These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31778904)

  • 1. A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma.
    Rettenmaier MA; Micha JP; Bohart R; Goldstein BH
    Eur J Obstet Gynecol Reprod Biol; 2020 Jan; 244():101-105. PubMed ID: 31778904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience.
    Mendivil AA; Rettenmaier MA; Abaid LN; Brown JV; Mori KM; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):405-410. PubMed ID: 28669065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma.
    Rettenmaier MA; Mendivil AA; Abaid LN; Brown Iii JV; Wilcox AM; Goldstein BH
    Int J Hyperthermia; 2015 Feb; 31(1):8-14. PubMed ID: 25559985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study.
    Vrdoljak J; Boban T; Petrić Miše B; Boraska Jelavić T; Bajić Ž; Tomić S; Vrdoljak E
    Jpn J Clin Oncol; 2019 Apr; 49(4):347-353. PubMed ID: 30796833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
    Shi T; Jiang R; Pu H; Yang H; Tu D; Dai Z; Cai Y; Zhang Y; Cheng X; Jia H; Tu R; Wang H; Tang J; Luan Y; Cai S; Zang R;
    Br J Cancer; 2019 Aug; 121(5):425-428. PubMed ID: 31383985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
    Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
    Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
    Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study.
    He X; Wei L; Li R; Jing S; Jia L; Ji D; Li Y; Wang Y; Zhu Y
    BMC Cancer; 2021 Jun; 21(1):738. PubMed ID: 34176478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study.
    Safra T; Grisaru D; Inbar M; Abu-Abeid S; Dayan D; Matceyevsky D; Weizman A; Klausner JM
    J Surg Oncol; 2014 Nov; 110(6):661-5. PubMed ID: 24962381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma.
    Rettenmaier MA; Mendivil AA; Abaid LN; Brown JV; Micha JP; Wilcox AM; Goldstein BH
    Arch Gynecol Obstet; 2015 Jun; 291(6):1381-6. PubMed ID: 25516177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.
    Bakrin N; Bereder JM; Decullier E; Classe JM; Msika S; Lorimier G; Abboud K; Meeus P; Ferron G; Quenet F; Marchal F; Gouy S; Morice P; Pomel C; Pocard M; Guyon F; Porcheron J; Glehen O;
    Eur J Surg Oncol; 2013 Dec; 39(12):1435-43. PubMed ID: 24209430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.
    Lim PQ; Han IH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.
    Gouy S; Ferron G; Glehen O; Bayar A; Marchal F; Pomel C; Quenet F; Bereder JM; Le Deley MC; Morice P
    Gynecol Oncol; 2016 Aug; 142(2):237-42. PubMed ID: 27246305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal paclitaxel and cisplatin compared with dose-dense paclitaxel and carboplatin for patients with stage III ovarian cancer.
    Murphy M; Martin G; Mahmoudjafari Z; Bivona C; Grauer D; Henry D
    J Oncol Pharm Pract; 2020 Oct; 26(7):1566-1574. PubMed ID: 31948348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study.
    D'Hondt V; Goffin F; Roca L; Dresse D; Leroy C; Kerger J; Cordier L; de Forges H; Veys I; Liberale G
    Int J Gynecol Cancer; 2016 Jun; 26(5):912-7. PubMed ID: 27051055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
    Argenta PA; Sueblinvong T; Geller MA; Jonson AL; Downs LS; Carson LF; Ivy JJ; Judson PL
    Gynecol Oncol; 2013 Apr; 129(1):81-5. PubMed ID: 23352917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer.
    Huang CY; Cheng M; Lee NR; Huang HY; Lee WL; Chang WH; Wang PH
    Int J Environ Res Public Health; 2020 Mar; 17(7):. PubMed ID: 32224896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal chemotherapy for ovarian cancer with peritoneal metastases, systematic review of the literature and focused personal experience.
    Coccolini F; Fugazzola P; Montori G; Ansaloni L; Chiarugi M
    J Gastrointest Oncol; 2021 Apr; 12(Suppl 1):S144-S181. PubMed ID: 33968435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.